A total of 19 subjects with PROC were treated in the study’s dose ... without any dose-limiting toxicity or cytokine release syndrome observed. Sonnet BioTherapeutics chief medical officer Richard ...

Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010 - Watch the "What This Means" video ...

Sonnet Technologies is expanding the power and ... that houses up to three Mac mini units side by side in a standard 19-inch rack. Its 2U design features front-to-back airflow, front panel access ...

PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs ...